Probiotics (Multi-Strain)

The probiotic industry sells “multi-strain” blends as if combining 12 bacterial species automatically produces 12 health benefits. It does not. Probiotics are the clearest example in supplements of why strain-specificity matters: Lactobacillus rhamnosus GG has strong evidence for pediatric diarrhea, but Lactobacillus rhamnosus ATCC 53103 may not. Saccharomyces boulardii CNCM I-745 prevents antibiotic-associated diarrhea; a generic “S. boulardii” from an unverified source may be a different strain entirely. The gap between marketing and evidence here is vast.

The mechanism is plausible but non-specific. Beneficial bacteria produce short-chain fatty acids (butyrate, propionate, acetate) that nourish colonocytes and regulate immune signaling. They compete with pathogens for adhesion sites and nutrients. They modulate tight junction proteins that maintain intestinal barrier integrity. But each strain does this differently, at different doses, in different host contexts. A multi-strain product containing 50 billion CFU split across 12 strains means each strain is present at ~4 billion CFU — often below the therapeutic threshold demonstrated in trials for that specific strain.

The IBS evidence illustrates the problem. Ford et al. (2018) meta-analyzed 53 RCTs of probiotics for irritable bowel syndrome and concluded that “particular combinations of probiotics, or specific species and strains, appeared to have beneficial effects on global IBS symptoms and abdominal pain, but it was not possible to draw definitive conclusions about their efficacy.” This is the scientific equivalent of “some things help some people sometimes, but we cannot tell you which things or which people.” The heterogeneity was so high that pooled effect estimates were unreliable.

The strain-specific evidence that does exist is strong for specific indications. Szajewska et al. (2015) meta-analysis of Lactobacillus rhamnosus GG for antibiotic-associated diarrhea found it reduced risk from 22.4% to 12.3% in children and adults, with the effect driven primarily by pediatric data. Saccharomyces boulardii has consistent meta-analytic evidence for preventing antibiotic-associated diarrhea and C. difficile recurrence. But these are single-strain, specific-dose interventions — not the generic multi-strain products dominating store shelves.

The safety signal is underappreciated. The PROPATRIA trial (Besselink et al., 2008) randomized patients with predicted severe acute pancreatitis to a multi-strain probiotic or placebo. The probiotic group had significantly higher mortality (16% vs 6%) and more bowel ischemia episodes. The mechanism is thought to be bacterial translocation in the setting of gut barrier failure and splanchnic hypoperfusion. This is not a theoretical risk — it is a documented, trial-demonstrated risk in critically ill patients.

The honest framing: if you have a specific indication with strain-specific evidence, use that strain at that dose. For general “gut health,” the evidence for multi-strain blends is weak and heterogeneous. Probiotics are not harmless — they are live microorganisms that can cause infections in immunocompromised hosts and worsen outcomes in critical illness. Do not take them “just because” or assume more strains and higher CFU counts mean better results.

Practical guidance: if recovering from antibiotics, consider S. boulardii (10 billion CFU/day) or L. rhamnosus GG (10 billion CFU/day) during and for 1-2 weeks after the course. For IBS, work with a gastroenterologist to identify strain-specific options with evidence. For general wellness, focus on dietary fiber (prebiotics) that feeds your existing microbiome rather than adding new strains with unproven benefit. Always separate probiotics from antibiotics by at least 2 hours.